Keyphrases
Open-label Extension
100%
Long-term Safety
100%
Long-term Efficacy
100%
Focal Segmental Glomerulosclerosis
100%
Sparsentan
100%
Proteinuria Reduction
26%
Irbesartan
20%
Blood Pressure
13%
Hypotension
13%
Safety Profile
13%
Partial Remission
13%
Endothelin-1 (ET-1)
13%
Peripheral Edema
13%
Protein-to-creatinine Ratio
13%
Treatment-related Adverse Events
13%
Randomized Double-blind
6%
Heart Failure
6%
Effective Treatment
6%
Long-term Treatment
6%
Headache
6%
Angiotensin II (Ang II)
6%
Single Molecule
6%
Treatment Duration
6%
Adverse Effects
6%
Continuation Treatment
6%
Upper Respiratory Tract Infection
6%
Hyperkalemia
6%
Median Time
6%
Estimated Glomerular Filtration Rate
6%
Angiotensin Receptor Antagonists
6%
Patient Death
6%
Safe Treatment
6%
Kidney Lesions
6%
Unmet Medical Need
6%
Plain Language Summary
6%
Estimated Glomerular Filtration Rate Decline
6%
Reduced Kidney Function
6%
Time to Treatment Discontinuation
6%
Medicine and Dentistry
Sparsentan
100%
Focal Segmental Glomerulosclerosis
100%
Proteinuria
26%
Adverse Event
20%
Irbesartan
20%
Urinary System
13%
Blood Pressure
13%
Hypotension
13%
Glomerular Filtration Rate
13%
Creatinine
13%
Peripheral Edema
13%
Heart Failure
6%
Kidney Function
6%
Angiotensin II
6%
Medicine
6%
Angiotensin Receptor Antagonist
6%
Kidney Injury
6%
Endothelin 1
6%
Upper Respiratory Tract Infection
6%
Headache
6%
Hyperkalemia
6%
Time to Treatment
6%
Immunosuppressive Drug
6%
Endothelin
6%
Pharmacology, Toxicology and Pharmaceutical Science
Focal Glomerulosclerosis
100%
Sparsentan
100%
Proteinuria
26%
Adverse Event
20%
Irbesartan
20%
Remission
13%
Creatinine
13%
Hypotension
13%
Peripheral Edema
13%
Heart Failure
6%
Headache
6%
Angiotensin Receptor Antagonist
6%
Hyperkalemia
6%
Angiotensin II
6%
Kidney Injury
6%
Immunosuppressive Agent
6%
Endothelin 1
6%
Upper Respiratory Tract Infection
6%
Endothelin
6%